{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T12:27:36Z","timestamp":1791635256025,"version":"4.3.4"},"reference-count":26,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T00:00:00Z","timestamp":1764460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Servier and Rovi to the Spanish Society of Cardiology"},{"name":"Rovi"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objectives: The aim was to evaluate the clinical features, management and 1-year outcomes in patients with heart failure (HF) and advanced chronic kidney disease (CKD) who were followed in specialized HF units in Spain. Methods: Data from the registry of the SEC-Excellent-HF quality program of the Spanish Society of Cardiology were analyzed. This registry included 1567 patients between 2019 and 2022 followed by 45 specialized HF units. Clinical features, treatment and 1-year rate of events (death and HF hospitalizations) were compared between the groups of advanced CKD (glomerular filtration rate &lt;30 mL\/minute\/m2) and GFR \u2265 30 mL\/min\/m2. Results: 11.1% of patients had a GFR &lt; 30 and 88.9% \u2265 30 mL\/min\/m2. The median LVEF was similar in groups with GFR &lt; 30 and \u226530 mL\/min\/m2: 42% (IQR 30\u201358) versus 38% (IQR 29\u201354). Advanced CKD patients were older, had more severe HF (previous HF admissions in the last year, worse NYHA functional class and longer evolution time) and had higher prevalence of ischemic heart disease, diabetes mellitus, systemic hypertension, iron deficiency, anemia and hyponatremia. All drugs for HF, except for diuretics and potassium binders, were used in a lower proportion in patients with GFR &lt; 30 mL\/min\/m2 (p &lt; 0.001). One-year overall mortality (49.2 versus 13.7\/100 patients-year; p &lt; 0.001) and one-year HF hospitalizations rate (83.2 versus 30.7\/100 patients-year; p &lt; 0.001) were higher in the group of advanced CKD. Conclusions: In our study, patients with advanced CKD had different clinical characteristics, received indicated treatment in a lower proportion and had higher 1-year rates of death and HF admissions.<\/jats:p>","DOI":"10.3390\/jcm14238508","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:20:29Z","timestamp":1765210829000},"page":"8508","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Features and Outcomes of Patients with Heart Failure and Advanced Chronic Kidney Disease"],"prefix":"10.3390","volume":"14","author":[{"given":"Mar\u00eda","family":"Anguita-G\u00e1mez","sequence":"first","affiliation":[{"name":"Instituto Cardiovascular, Hospital Cl\u00ednico San Carlos, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Herrera-Flores","sequence":"additional","affiliation":[{"name":"UGC de Cardiolog\u00eda, Hospital Universitario Reina Sof\u00eda, Universidad de C\u00f3rdoba, Instituto Maim\u00f3nides de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba (IMIBIC), 14004 C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9417-1868","authenticated-orcid":false,"given":"Juan L.","family":"Bonilla-Palomas","sequence":"additional","affiliation":[{"name":"Unidad de Cardiolog\u00eda, Hospital San Juan de la Cruz, 23400 \u00dabeda, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Recio-Mayoral","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen Macarena, 41009 Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8446-7369","authenticated-orcid":false,"given":"Rafael","family":"Gonz\u00e1lez-Manzanares","sequence":"additional","affiliation":[{"name":"UGC de Cardiolog\u00eda, Hospital Universitario Reina Sof\u00eda, Universidad de C\u00f3rdoba, Instituto Maim\u00f3nides de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba (IMIBIC), 14004 C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3164-0823","authenticated-orcid":false,"given":"Juan C.","family":"Castillo Dom\u00ednguez","sequence":"additional","affiliation":[{"name":"UGC de Cardiolog\u00eda, Hospital Universitario Reina Sof\u00eda, Universidad de C\u00f3rdoba, Instituto Maim\u00f3nides de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba (IMIBIC), 14004 C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"L\u00f3pez-Aguilera","sequence":"additional","affiliation":[{"name":"UGC de Cardiolog\u00eda, Hospital Universitario Reina Sof\u00eda, Universidad de C\u00f3rdoba, Instituto Maim\u00f3nides de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba (IMIBIC), 14004 C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Mu\u00f1iz","sequence":"additional","affiliation":[{"name":"Grupo de Investigaci\u00f3n Cardiovascular, Departamento de Ciencias de la Salud e Instituto de Investigaci\u00f3n Biom\u00e9dica de A Coru\u00f1a (INIBIC), Universidade da Coru\u00f1a, 15006 A Coru\u00f1a, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBER CV), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Anguita-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"UGC de Cardiolog\u00eda, Hospital Universitario Reina Sof\u00eda, Universidad de C\u00f3rdoba, Instituto Maim\u00f3nides de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba (IMIBIC), 14004 C\u00f3rdoba, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBER CV), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,30]]},"reference":[{"key":"ref_1","first-page":"1041","article-title":"Prevalence of heart failure in Spanish general population aged over 45 years. The PRICE study","volume":"61","author":"Navarro","year":"2008","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/ejhf.813","article-title":"Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced dejection fraction: An analysis of the ESC Heart Failure Lon-Term Registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalized or ambulatory patients with heart failure treated in accordance with ESC guidelines? Evidence from 12.440 patients of the ESC Heart Failure Long-term registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur. J. Heart Fail."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e13606","DOI":"10.1111\/eci.13606","article-title":"Thirteen-year trends in hospitalization and outcomes of patients with heart failure in Spain","volume":"51","year":"2021","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_6","first-page":"1075","article-title":"Temporal trends in hospitalizations and in-hospital mortality in heart failure in Spain 2003\u20132015, differences between autonomous communities","volume":"73","year":"2020","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.kint.2019.02.022","article-title":"Heart failure in chronic kidney disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"House","year":"2019","journal-title":"Kidney Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1681\/ASN.2006101159","article-title":"Reduced kidney function as a risk factor for incident heart failure: The Atherosclerosis Risk In Communities (ARIC) study","volume":"18","author":"Kottgen","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1053\/j.ajkd.2019.09.003","article-title":"US Renal Data System 2019 annual data report: Epidemiology of kidney disease in the United States","volume":"75","author":"Saran","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1136\/heartjnl-2018-314158","article-title":"Change in renal function associated with drug treatment in heart failure: National guidance","volume":"105","author":"Clark","year":"2019","journal-title":"Heart"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/heartjnl-2017-311652","article-title":"Drug treatment effects on outcomes in heart failure with preserved ejection fraction: A systematic review and meta-analysis","volume":"104","author":"Zheng","year":"2018","journal-title":"Heart"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"ref_18","first-page":"602","article-title":"Improving the quality of health care. Results of the SEC-Excelente accreditation program in heart failure of the Spanish Society of Cardiology","volume":"77","year":"2024","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/eurjhf\/hft050","article-title":"EURObservational Research programme: Regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot)","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur. J. Heart Fail."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ejhf.486","article-title":"Thirty-year trends in heart failure hospitalization and mortality rates and the prognostic impact of comorbidity: A Danish nation-wide cohort study","volume":"18","author":"Schmidt","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1001\/jamacardio.2019.3593","article-title":"Temporal trends and patterns in mortality after incident heart failure: A longitudinal analysis of 86,000 individuals","volume":"4","author":"Conrad","year":"2019","journal-title":"JAMA Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00392-023-02202-7","article-title":"One-year readmissions for circulatory diseases and in-hospital mortality after an index episode of heart failure in elderly patients. A nationwide data from public hospitals in Spain between 2016 and 2018","volume":"112","author":"Rosillo","year":"2023","journal-title":"Clin. Res. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.jchf.2023.07.029","article-title":"Sex differences in heart failure with reduced ejection fraction in the GALACTIC-HF trial","volume":"11","author":"Pabon","year":"2023","journal-title":"JACC Heart Fail."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N. Eng. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Agarwal, R., Green, J.B., Heerspink, H.J., Mann, J.F., McGill, J.B., Mottl, A.K., Rosenstock, J., Rossing, P., Vaduganathan, M., and Brinker, M. (2025). Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. N. Eng. J. Med.","DOI":"10.1056\/NEJMoa2410659"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1159\/000541393","article-title":"Efficacy of Modern Therapies for Heart Failure with Reduced Ejection Fraction in Specific Population Subgroups: A Systematic Review and Network Meta-Analysis","volume":"14","author":"Lavalle","year":"2024","journal-title":"Cardiorenal Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/23\/8508\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:29:24Z","timestamp":1765211364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/23\/8508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,30]]},"references-count":26,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["jcm14238508"],"URL":"https:\/\/doi.org\/10.3390\/jcm14238508","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,30]]}}}